peptide pnc 27 PNC-27 is a membrane-active anticancer research peptide - PNC-27 protocol PNC-27 is a peptide synthesized of amino acids of the p53-HDM2-binding domain Understanding the Anti-Cancer Peptide PNC-27: Mechanism, Efficacy, and Research

PNC-27 reviews PNC-27 is an innovative anti-cancer peptide that has garnered significant attention in the scientific community for its unique mechanism of action and selective cytotoxicity against cancer cells. This peptide PNC-27 is a chimeric peptide, meaning it is composed of distinct functional domains. Specifically, it integrates a p53-HDM2-binding domain with a cell-penetrating peptide (CPP) leader sequence. This structural design is key to its ability to target and destroy cancerous cells while leaving healthy cells unharmedAbstract #884: Mechanism of action of PNC-27/-28 anti-cancer ....

The primary mechanism by which PNC-27 operates involves its interaction with the HDM-2 protein. This protein is frequently overexpressed on the membranes of various tumor cells中文名称：:PNC-27肽. 英文名称：: PNC-27. CAS号：: 1159861-00-3. 品牌：: Molcoo. 产地：: 武汉. 保存条件：: -20℃下冷冻干燥、避光保存.. PNC-27 targets HDM-2 in the membranes of cancer cells, leading to a specific and targeted disruption.2025年11月22日—PNC-27 is an experimental anticancer peptidethat has shown promising preclinical activity in laboratory studies but has not been validated ... Upon binding to HDM-2, PNC-27 induces the formation of transmembrane pores. This process, known as membranolysis, causes the cancer cells to rupture and undergo necrosis, effectively eliminating them.Targeting Membrane HDM-2 by PNC-27 Induces Necrosis in ... Research indicates that PNC-27 induces cancer cell membrane lysis by acting as the whole peptide, not through fragmentation. Studies have also shown that PNC-27 adopts an HDM-2-binding conformation, which is crucial for its cytotoxic effects.

The selectivity of PNC-27 is a critical aspect of its therapeutic potential.Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique ... Unlike many traditional chemotherapies that can cause significant damage to healthy tissues, PNC-27 is cytotoxic to cancer cells but has been demonstrated to have no effect on normal cells. This selective action minimizes the adverse side effects often associated with cancer treatment, making it a promising candidate for further development. The efficiency of anti-cancer peptides PNC-27 has been observed in both in vivo and in vitro studies, suggesting its broad applicabilityPNC-27 is a membrane active anticancer peptidethat has been found to kill cancer cells by inducing membranolytic via cellular necrosis..

The development of PNC-27 is rooted in understanding the interaction between p53 and HDM-2. HDM-2 is a protein that normally regulates the stability of the tumor suppressor protein p53. By binding to HDM-2, PNC-27 can disrupt this regulatory interaction, potentially influencing cellular processes related to cancer. The p53-HDM2-binding domain within PNC-27 is specifically designed to interfere with this pathway.作者：AI Miller—The anti-cancer peptide, PNC-27,is cytotoxic to cancer cellsbut has no effect on normal cells and has eradicated tumors in vivo with no off-target effects. We ...

While PNC-27 has shown promising preclinical activity, it is important to note its current status. PNC-27 is an experimental anticancer peptide. The U.S作者：M Silberstein·被引用次数：1—They also noted that thePNC-27 peptidecould cause cell destruction through membranolysis through the same HDM-2 binding mechanism as it did in the solid.. Food and Drug Administration (FDA) has stated that FDA has not evaluated or approved PNC-27 as safe and effective to treat any disease, including any form of cancer.作者：K Davitt·2014·被引用次数：25—We have developed the anti-cancer peptide,PNC-27, which is a membrane-active peptide that binds to the HDM-2 protein expressed in the cancer cell membranes. Therefore, its use is currently limited to research settings, and it is not approved for clinical use in patients作者：E Sarafraz-Yazdi·2015·被引用次数：12—. Anti-cancer peptide, PNC-27,adopts an HDM2-binding conformationand kills cancer cells by binding to HDM2 in their membranes..

Despite the lack of FDA approval, research continues to explore the potential of PNC-27. Various studies have investigated its efficacy in different cancer types. For instance, some research has focused on its effectiveness against cervical cancer, with studies indicating that PNC-27 targets cervical cancer with enhanced efficacy. Furthermore, PNC-27 has eradicated tumors in vivo with no off-target effects reported in some preclinical investigations. The PNC-27 peptide is a subject of ongoing research, with efforts to understand its full therapeutic capabilities and potential applications.

The PNC-27 acetate is a form of the peptide that is also being studied. Like PNC-27, it functions as a chimeric p53-penetratin peptide that binds to HDM-2, promoting selective pore formation in cancer cell membranes and leading to cell lysis. This compound is also being explored for its potential in acute myeloid leukemia research.

The scientific literature details the synthesis and properties of PNC-27, with some sources noting its CAS number as 1159861-00-3Anticancer peptide PNC-27 adopts an HDM-2-binding .... It is typically stored at -20°C under lyophilized, light-protected conditions. Researchers are also exploring related compounds, such as PNC-28, for their anti-cancer properties.

In summary, PNC-27 is a membrane-active anticancer peptide that selectively targets cancer cells by binding to HDM-2 on their membranes, inducing pore formation and cell death through necrosis. While its preclinical results are encouraging, it remains an experimental compound and is not yet approved for medical use. Continued research aims to fully elucidate its therapeutic potential and safety profile.The anti-cancer peptide, PNC-27, induces tumor cell ...